Article
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
Journal of the Formosan Medical Association = Taiwan yi zhi - 1 Aug 2022
Lo Ching-Chu, Huang Chung-Feng, Cheng Pin-Nan, Tseng Kuo-Chih, Chen Chi-Yi, Kuo Hsing-Tao, Huang Yi-Hsiang, Tai Chi-Ming, Peng Cheng-Yuan, Bair Ming-Jong, Chen Chien-Hung, Yeh Ming-Lun, Lin Chih-Lang, Lin Chun-Yen, Lee Pei-Lun, Chong Lee-Won, Hung Chao-Hung, Chang Te Sheng, Huang Jee-Fu, Yang Chi-Chieh, Hu Jui-Ting, Lin Chih-Wen, Chen Chun-Ting, Wang Chia-Chi, Su Wei-Wen, Hsieh Tsai-Yuan, Lin Chih-Lin, Tsai Wei-Lun, Lee Tzong-Hsi, Chen Guei-Ying, Wang Szu-Jen, Chang Chun-Chao, Mo Lein-Ray, Yang Sheng-Shun, Wu Wen-Chih, Huang Chia-Sheng, Hsiung Chou-Kwok, Kao Chien-Neng, Tsai Pei-Chien, Liu Chen-Hua, Lee Mei-Hsuan, Liu Chun-Jen, Dai Chia-Yen, Chuang Wan-Long, Lin Han-Chieh, Kao Jia-Horng, Yu Ming-Lung
Abstract excerpt
BACKGROUND/PURPOSE: The Taiwan Association for the Study of the Liver (TASL) HCV Registry (TACR) is a nationwide registry of chronic hepatitis C patients in Taiwan. This study evaluated antiviral effectiveness of ledipasvir (LDV)/sofosbuvir (SOF) in patients in the TACR. METHODS: Patients enrolled in TACR from 2017-2020 treated with LDV/SOF were eligible. The primary outcome was the proportion of patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.